Travere Therapeutics

At the Cantor Fitzgerald Healthcare Conference, Travere Therapeutics presented a growth plan focused on FILSPARI, which is expected to generate strong sales in IgA nephropathy and a rapid launch in FSGS following approval in April. Management sees peak sales potential for FILSPARI of more than $3 billion and reports a solid cash position of $489 million with no near‑term need for capital. Pegtibatinase (Phase III results expected H2 2027) and civorebrutinib broaden the pipeline but will require further development before contributing commercially. Travere emphasizes expanding market penetration, payer access, and scaling manufacturing to support future growth. » More on de.investing.com

Travere Therapeutics’ stock hit a new 52-week high of $68.25 and is up substantially year-to-date (12 months +172.32%, YTD +73%, 6 months +131%). In Q2 the company reported revenue of $169.6m, beating consensus; the driver was the kidney drug FILSPARI with sales of $141.1m (+96% year‑over‑year). Cash and cash equivalents amounted to about $489.2m, and InvestingPro rates the financial position as "VERY GOOD" but, according to its fair‑value assessment, considers the stock overvalued. Stifel raised its price target to $62 and reiterated a "Hold" rating in light of strong demand for FILSPARI. » More on de.investing.com

Travere Therapeutics' stock rose to a 52-week high of $68.03 and delivered a year-to-date return of about 243%. In the second quarter the company reported revenue of $169.6 million, driven by FILSPARI sales, which increased to $141.1 million (+96% year-over-year); U.S. net product sales were $161.4 million. Travere held roughly $489.2 million in cash and marketable securities, and Stifel raised its price target to $62 while reiterating its rating. » More on de.investing.com